New England Asset Management Inc. Trims Stake in Johnson & Johnson (NYSE:JNJ)

New England Asset Management Inc. reduced its position in Johnson & Johnson (NYSE:JNJ) by 0.6% during the second quarter, HoldingsChannel.com reports. The firm owned 31,457 shares of the company’s stock after selling 200 shares during the period. New England Asset Management Inc.’s holdings in Johnson & Johnson were worth $4,381,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of JNJ. Thoroughbred Financial Services LLC increased its position in shares of Johnson & Johnson by 14,147.0% during the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after acquiring an additional 3,986,071 shares during the period. Renaissance Technologies LLC boosted its stake in Johnson & Johnson by 145.5% in the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock valued at $604,637,000 after acquiring an additional 2,572,695 shares in the last quarter. APG Asset Management N.V. boosted its stake in Johnson & Johnson by 61.4% in the second quarter. APG Asset Management N.V. now owns 5,188,736 shares of the company’s stock valued at $634,604,000 after acquiring an additional 1,973,700 shares in the last quarter. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 0.7% in the second quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock valued at $31,360,143,000 after acquiring an additional 1,627,370 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in Johnson & Johnson by 14.2% in the first quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after acquiring an additional 1,079,751 shares in the last quarter. 72.01% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE JNJ traded up $1.54 during midday trading on Friday, reaching $131.65. The company had a trading volume of 11,063,023 shares, compared to its average volume of 7,269,268. The business’s 50-day simple moving average is $130.02 and its 200 day simple moving average is $135.71. The stock has a market cap of $344.17 billion, a P/E ratio of 16.09, a P/E/G ratio of 2.21 and a beta of 0.68. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.



Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the company posted $2.10 earnings per share. Analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $0.95 per share. The ex-dividend date was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.89%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

Several equities research analysts have weighed in on JNJ shares. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a research note on Thursday, July 18th. Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $150.60.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.